Table 4. Treatment and outcome.
| Case | Age | Sex | Diagnosis | Surgical management | Medical management | Other therapies | Outcome, time after ECS diagnosis | Control of hypercortisolism |
|---|---|---|---|---|---|---|---|---|
| 1 | 32 | M | Occult | Bilateral adrenalectomy | Ketoconazol* 800 mg/d | - | Occult ( 1 month) | Yes |
| 2 | 28 | F | Metastatic medullary thyroid carcinoma | Thyroidectomy + bilateral adrenalectomy+ thrombectomy of inferior vena cava . | Somatostatin analogue | Death (3 months), disease progression | Yes | |
| 3 | 46 | F | Well-differentiated pancreatic neuroendocrine tumor | Distal pancreatectomy + open bilateral adrenalectomy | - | - | Alive (132 months) | Yes |
| 4 | 31 | F | Lung carcinoid | Resection of lung tumor (1986-2006) | - | - | Alive (96 months) | Yes |
| 5 | 72 | F | Small-cell lung carcinoma | Bilateral adrenalectomy | - | Carboplatin, etoposide, dexamethasone | Death (febrile neutropenia – septic shock, 3 months) | Yes |
| 6 | 62 | M | Lung carcinoid with liver and bone metastases. | Lung lobectomy plus right bronchoplasty in 2004 | Ketoconazol 600 mg/d Octreotide LAR 30 mg/m | Liver trans-arterial chemo-embolization with doxorubicin | Death 29 months (pneumonia) | No |
| 7 | 68 | M | Probable small-cell lung carcinoma | - | Ketoconazol 400 mg/d | - | Death (respiratory failure/sepsis) 2 months | No |
| 8 | 77 | M | Grade 3 pancreatic neuroendocrine carcinoma with liver metastasis | - | Ketoconazol 800 mg/d Octreotide SC 0.3 mg sc q/d | - | Death, 15 months, disease progression | No |
| 9 | 70 | F | Lung carcinoid | Segmental lobectomy of medial lobe | Ketoconazol 600 mg/d* | - | Alive (27 months) | Yes |
| 10 | 59 | F | Pheochromocytoma | Laparoscopic right adrenalectomy | - | - | Alive (31 months) | Yes |
| 11 | 64 | F | Poorly-differentiated lung neuroendocrine carcinoma with liver metastasis | - | - | Carboplatin, etoposide, dexamethasone, | Death (septic shock, 1 month) | No |
| 12 | 68 | F | Grade 2 pancreatic neuroendocrine carcinoma with liver metastasis | Distal pancreatectomy | Ketoconazol 800 mg/d Octreotide LAR 30 mg/m | - | Death 27 months (disease progression) | Yes |
| 13 | 35 | M | Metastatic thymoma | - | Ketoconazol 600 mg/d | - | Alive (33 months) | Yes |
| 14 | 50 | M | Small-cell lung carcinoma | - | Ketoconazol 800 mg/d | Topotecan Cranial Radiotherapy | Death 22 days (disease progression) | Yes |
* Prior to tumor resection.